Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 9/20 | 0.46 |
| ▸ | HCRTR2 | O43614 | 9/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | ATR | Q13535 | 5/20 | 0.35 |
| ▸ | CYP46A1 | Q9Y6A2 | 1/20 | 0.35 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.34 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.34 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.33 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL440917 | 0.88 | HCRTR2 (0.44) | HCRTR1HCRTR2ATMATRCYP46A1 | |
| SCHEMBL438304 | 0.84 | HCRTR2 (0.61) | HCRTR1HCRTR2ATMATRCYP3A4 | |
| SCHEMBL7880401 | 0.77 | HCRTR1 (0.42) | HCRTR1HCRTR2ATMATRCYP3A4 | |
| SCHEMBL438348 | 0.75 | ATM (0.41) | HCRTR1HCRTR2ATMATRCYP11B1 | |
| SCHEMBL19406805 | 0.73 | IRAK4 (0.51) | HCRTR1HCRTR2ATMCYP46A1CYP11B1 | |
| SCHEMBL7877771 | 0.73 | HCRTR1 (0.57) | HCRTR1HCRTR2ATRCYP11B1CYP11B2 | |
| SCHEMBL441242 | 0.73 | LRRK2 (0.47) | HCRTR1HCRTR2ATM | |
| SCHEMBL4002550 | 0.72 | ATR (0.54) | HCRTR1HCRTR2ATR | |
| SCHEMBL14564459 | 0.68 | TDP1 (0.47) | CYP46A1CYP3A4 | |
| SCHEMBL24485254 | 0.67 | ALDH1A1 (0.46) | CYP46A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2438041-A1 | PYRAZINE CARBOXAMIDE OREXIN RECEPTOR ANTAGONISTS | Merck Sharp & Dohme Corp. (US) | 2012-04-11 | — | — | EP | disclosed |
| US-20120065205-A1 | PYRAZINE CARBOXAMIDE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. | 2012-03-15 | — | — | US | disclosed |
| WO-2010141275-A1 | PYRAZINE CARBOXAMIDE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2010-12-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065205-A1 | PYRAZINE CARBOXAMIDE OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, NPY5R | HCRTR1 2/4885HCRTR2 1/4885ATM 4830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.